Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TDG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TDG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TDG_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TDG_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TDG_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003465519 | Esophagus | HGIN | nucleobase-containing compound catabolic process | 98/2587 | 407/18723 | 1.44e-08 | 8.94e-07 | 98 |
GO:004670017 | Esophagus | HGIN | heterocycle catabolic process | 103/2587 | 445/18723 | 5.44e-08 | 2.99e-06 | 103 |
GO:004427018 | Esophagus | HGIN | cellular nitrogen compound catabolic process | 103/2587 | 451/18723 | 1.10e-07 | 5.56e-06 | 103 |
GO:001943917 | Esophagus | HGIN | aromatic compound catabolic process | 105/2587 | 467/18723 | 1.89e-07 | 9.31e-06 | 105 |
GO:000632516 | Esophagus | HGIN | chromatin organization | 92/2587 | 409/18723 | 1.05e-06 | 4.16e-05 | 92 |
GO:190136117 | Esophagus | HGIN | organic cyclic compound catabolic process | 106/2587 | 495/18723 | 1.94e-06 | 7.13e-05 | 106 |
GO:00196924 | Esophagus | HGIN | deoxyribose phosphate metabolic process | 16/2587 | 42/18723 | 7.90e-05 | 1.76e-03 | 16 |
GO:00092624 | Esophagus | HGIN | deoxyribonucleotide metabolic process | 16/2587 | 44/18723 | 1.51e-04 | 2.97e-03 | 16 |
GO:00093944 | Esophagus | HGIN | 2'-deoxyribonucleotide metabolic process | 15/2587 | 40/18723 | 1.62e-04 | 3.16e-03 | 15 |
GO:00092643 | Esophagus | HGIN | deoxyribonucleotide catabolic process | 12/2587 | 30/18723 | 3.62e-04 | 5.68e-03 | 12 |
GO:00463863 | Esophagus | HGIN | deoxyribose phosphate catabolic process | 12/2587 | 31/18723 | 5.17e-04 | 7.46e-03 | 12 |
GO:000911720 | Esophagus | HGIN | nucleotide metabolic process | 92/2587 | 489/18723 | 1.11e-03 | 1.36e-02 | 92 |
GO:000675320 | Esophagus | HGIN | nucleoside phosphate metabolic process | 93/2587 | 497/18723 | 1.25e-03 | 1.49e-02 | 93 |
GO:00092233 | Esophagus | HGIN | pyrimidine deoxyribonucleotide catabolic process | 8/2587 | 19/18723 | 2.40e-03 | 2.41e-02 | 8 |
GO:0006285 | Esophagus | HGIN | base-excision repair, AP site formation | 6/2587 | 12/18723 | 3.03e-03 | 2.88e-02 | 6 |
GO:00092193 | Esophagus | HGIN | pyrimidine deoxyribonucleotide metabolic process | 9/2587 | 24/18723 | 3.33e-03 | 3.12e-02 | 9 |
GO:00062442 | Esophagus | HGIN | pyrimidine nucleotide catabolic process | 8/2587 | 21/18723 | 5.00e-03 | 4.19e-02 | 8 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TDG | SNV | Missense_Mutation | novel | c.40N>C | p.Ala14Pro | p.A14P | Q13569 | protein_coding | tolerated_low_confidence(0.07) | benign(0.087) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
TDG | SNV | Missense_Mutation | novel | c.422N>T | p.Pro141Leu | p.P141L | Q13569 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TDG | SNV | Missense_Mutation | novel | c.1015N>C | p.Glu339Gln | p.E339Q | Q13569 | protein_coding | deleterious(0.05) | benign(0.282) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TDG | SNV | Missense_Mutation | novel | c.253T>C | p.Ser85Pro | p.S85P | Q13569 | protein_coding | tolerated(0.31) | benign(0.216) | TCGA-A6-2675-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TDG | SNV | Missense_Mutation | | c.1114N>A | p.Glu372Lys | p.E372K | Q13569 | protein_coding | tolerated_low_confidence(0.1) | benign(0.021) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TDG | SNV | Missense_Mutation | | c.651N>T | p.Gln217His | p.Q217H | Q13569 | protein_coding | deleterious(0) | benign(0.394) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TDG | SNV | Missense_Mutation | | c.553T>A | p.Tyr185Asn | p.Y185N | Q13569 | protein_coding | deleterious(0.01) | possibly_damaging(0.782) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TDG | SNV | Missense_Mutation | novel | c.1158G>C | p.Gln386His | p.Q386H | Q13569 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.998) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TDG | SNV | Missense_Mutation | novel | c.1018G>T | p.Ala340Ser | p.A340S | Q13569 | protein_coding | tolerated(0.17) | benign(0.135) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
TDG | SNV | Missense_Mutation | novel | c.133C>T | p.Pro45Ser | p.P45S | Q13569 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |